Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,121 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rheumatoid Arthritis Clear all
Completed Phase 2 Interventional Results available

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871
View directory record Official record
Conditions
Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Interventions
branebrutinib, abatacept, branebrutinib placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Covina, California • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 19, 2026, 8:30 PM EDT
Not listed Not applicable Interventional

Trinity™ BIOLOX Delta™ CoC THR Multi-center Study

NCT01921309
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, CDH
Interventions
Trinity CoC Total Hip System, Trinity Ceramic-on-Poly THR
Device
Lead sponsor
Corin
Industry
Eligibility
18 Years to 80 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Parker, Colorado • Hartford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 4 Interventional Results available

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

NCT01400516
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Teriparatide, calcium citrate, Vitamin D, TNF antagonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 19, 2026, 8:30 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 19, 2026, 8:30 PM EDT
Active, not recruiting Not applicable Interventional

At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

NCT07163221
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1, Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2, Sham ultrasound stimulation (control), Conventional Synthetic DMARD
Device · Drug
Lead sponsor
SecondWave Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Glendale, Arizona • Covina, California • Temecula, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Not applicable Interventional

GIOP Prevention Among People With Rheumatoid Arthritis

NCT00609830
View directory record Official record
Conditions
Osteoporosis, Rheumatoid Arthritis
Interventions
Tailored Materials, Tailored Materials Plus Physician Feedback, Generic Materials, No Information
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

NCT02147587
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
36
States / cities
Jonesboro, Arkansas • Los Angeles, California • Santa Maria, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 19, 2026, 8:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Metagenomic Biomarkers in Rheumatoid Arthritis

NCT02544334
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Dental Plaque, Multi-dimensional health assessment questionnaire (MDHAQ), Saliva Collection
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 19, 2026, 8:30 PM EDT
Completed No phase listed Observational

Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study

NCT00341198
View directory record Official record
Conditions
Autoimmune Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Iowa City, Iowa • Durham, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 8:30 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 19, 2026, 8:30 PM EDT
Completed No phase listed Observational

Study of Oral Bacteria in Patients With Dry Mouth

NCT00048685
View directory record Official record
Conditions
Xerostomia, Autoimmune Diseases
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 8:30 PM EDT
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Completed No phase listed Observational Results available

A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis

NCT04721808
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
Not listed
Enrollment
1,712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 2 Interventional Results available

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

NCT02093026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisolone, Folic Acid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
42
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

NCT04057118
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SKI-O-703, Placebo
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Beverly Hills, California • Upland, California • Miami Lakes, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of A Mailed Arthritis Self-Management Program

NCT00448474
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis
Interventions
Mailed Arthritis Self-Management Education
Behavioral
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2007 · Synced Oct 19, 2026, 8:30 PM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

NCT02353780
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
Drug
Lead sponsor
Dr. Larry W. Moreland
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 19, 2026, 8:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Ianalumab (VAY736), Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
32
States / cities
Fullerton, California • La Palma, California • Van Nuys, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Terminated Phase 2 Interventional

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

NCT01636817
View directory record Official record
Conditions
Inflammation, Rheumatoid Arthritis
Interventions
NNC0109-0012, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
92
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 19, 2026, 8:30 PM EDT
Terminated Phase 2 Interventional

INCB047986 in Rheumatoid Arthritis

NCT02151474
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
INCB047986, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Orange, California • DeBary, Florida • Palm Harbor, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 19, 2026, 8:30 PM EDT
Not listed Not applicable Interventional

Novel Splinting Technique Using 3D Models

NCT05351060
View directory record Official record
Conditions
Arthritis, Osteoarthritis Hand, Scleroderma, Systemic, Scleroderma, Diffuse, Rheumatoid Arthritis
Interventions
Custom Fabricated Splint
Other
Lead sponsor
Giovanna Fichera
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 19, 2026, 8:30 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 19, 2026, 8:30 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

NCT01955733
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695500
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 82 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 2Phase 3 Interventional

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334
View directory record Official record
Conditions
Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
Interventions
NC-503 (Anti-amyloidotic (AA) Agent)
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2006 · Synced Oct 19, 2026, 8:30 PM EDT